Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be attending and presenting at a series of investor events from the 11th February to 26th March 2020.
Cathal Friel, Open Orphan’s Executive Chairman, or Trevor Phillips, CEO, will be in attendance for all the events and will be presenting an update to existing and potential investors on the Company’s acquisition of hVIVO and business plans for 2020. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supporting product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. It also has Europe’s only commercial 24 bed quarantine clinic and on-site virology laboratory at Queen Mary’s Hospital in London.
A link to our investor presentation is available on our website at https://www.openorphan.com/sites/openorphan/files/Open%20Orphan%20Investor%20Deck_0.pdf
No new material information will be disclosed at any event.
A full schedule of the upcoming events is as follows:
|
Event |
Date/Time |
Location |
|
Shares Magazine/Cenkos Growth and Innovation Forum |
February 11, 2020 08:45 – 17:30 |
London – Business Design Centre, London N1 52 Upper Street, Islington
|
|
ShareSoc Growth Company Seminar |
February 25, 2020 18:00 – 20:40
|
Manchester – DoubleTree by Hilton Hotel, One Piccadilly Place, 1 Auburn Street, Manchester M1 3DG |
|
Shares Magazine Investor Event |
February 25, 2020 17:30 – 21:30 |
London – Novotel, Pepys Street, London |
|
ShareSoc Growth Company Seminar |
March 11, 2020 17:30 – 21:30 |
London – Company Matters/Link Asset Services, 65 GRESHAM STREET, London EC2V 7NQ |
|
ShareSoc Growth Company Seminar |
March 17, 2020 18:00 – 20:40 |
Birmingham – Clayton Hotel Birmingham, Albert Street, Birmingham B5 5JE |
|
Proactive Investors One2One Forum |
March 26, 2020 18:00 – 21:30 |
London – Chesterfield Mayfair Hotel, 35 Charles Street, London, W1J 5EB |
Enquiries:
Open Orphan plc
Cathal Friel, Executive Chairman +353 (0)1 644 0007
Trevor Phillips, Chief Executive Officer +44 (0)20 7347 5350
Arden Partners plc (Nominated Adviser and Joint Broker) +44 (0)20 7614 5900
John Llewellyn-Lloyd / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) +353 (0)1 679 6363
Anthony Farrell
Camarco (Financial PR) +44 (0)20 3757 4980
Tom Huddart / Daniel Sherwen
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
Notes to Editors:
Open Orphan is a rapidly growing European full pharmaceutical services company with a focus on orphan drug and specialist services, comprising two commercial specialist CRO services businesses (Venn and hVIVO) and a developing early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), preclinical, phase I & II clinical trials design and execution. hVIVO, as an industry leading services provider in viral challenge studies and vaccine and viral laboratory services, supports product development for customers developing antivirals, vaccines and respiratory therapeutics , all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The Merger with hVIVO created a European full pharma services company broadening the Company’s customer base and with complementary specialist CRO services, widening the range of the Company’s service offerings.